CLINICAL LEARNING GUIDE

TESAMORELIN

GHRH Analog | Egrifta | FDA-Approved

Mechanisms, Clinical Evidence & Provider Guidance

Based on lecture and slide materials by William Seeds, MD — SSRP Institute | Cellular Medicine Education

For educational and research purposes only. Not medical advice. Consult qualified healthcare providers.

SECTION 1 · PROFILE OF THE PEPTIDE

Overview

Tesamorelin (brand name Egrifta) is a synthetic analog of the 44-amino acid hypothalamic growth hormone-releasing hormone (GHRH). It received FDA approval in November 2010 and is indicated for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.

Generic Name	Tesamorelin
Brand Name(s)	Egrifta / Egrifta SV / Egrifta WR
Drug Class	Synthetic GHRH analogue (44-amino acid peptide)
FDA Approval Date	November 2010
Manufacturer	Theratechnologies Inc. (Montreal, Canada)
FDA Indication	Reduction of excess abdominal fat in HIV-infected patients with lipodystrophy
Route of Administration	Subcutaneous injection (abdomen)
Half-Life	~26 min (IV); ~38 min (SC)
Bioavailability	<4% absolute (SC)

Structural Distinction

Tesamorelin is a stabilized synthetic version of the native GHRH(1-44)NH_2 sequence. The key structural modification is the addition of a trans-3-hexanoic acid group at the N-terminal end, which:

- Dramatically enhances stability against dipeptidyl peptidase-4 (DPP-4) degradation
- Extends the half-life from ~5 minutes (native GHRH) to approximately 26–38 minutes
- Preserves the biological activity and receptor-binding capacity of endogenous GHRH

Clinical Significance at a Glance

- Phase 3 data demonstrated a 17.5% reduction in visceral adipose tissue (VAT) at 26 weeks
- Maintains the pulsatility of normal GH release — unlike exogenous growth hormone
- Preserves the natural negative feedback axis (somatostatin / IGF-1)
- Emerging evidence supports applications in fatty liver disease, cognitive function, neuroprotection, and muscle quality

SECTION 2 · MODES OF ACTION AND MECHANISMS

Primary Receptor Mechanism

Tesamorelin binds with high affinity to the growth hormone-releasing hormone receptor (GHRHR), a G protein-coupled receptor on somatotroph cells in the anterior pituitary. This initiates the following cascade:

1. Receptor binding → Adenylate cyclase activation → ↑ Cyclic AMP (cAMP)
2. ↑ cAMP → PKA activation → Stimulates GH gene transcription and protein synthesis
3. Pulsatile GH release → Mimics normal physiological secretion patterns
4. Feedback preserved → Somatostatin and IGF-1 feedback inhibition remains intact

Downstream Molecular Effects

GH / IGF-1 Axis	Pulsatile GH stimulates hepatic IGF-1 production within normal age-adjusted ranges
Lipolysis	Hormone-sensitive lipase (HSL) activation in visceral adipocytes → ↑ fatty acid release → enhanced beta-oxidation
Mitochondrial Function	AMPK upregulation, PGC-1α transcription, and mitochondrial biogenesis are all enhanced
De Novo Lipogenesis	Inhibited in the liver → reduces hepatic fat accumulation
Adiponectin	Increased — an anti-inflammatory adipokine supporting metabolic health
11β-HSD1 Inhibition	Reduces intracellular cortisol activation in muscle and brain (independent of peripheral adrenal output)
GABA Modulation	Increases GABA levels across 3 brain regions — inhibitory counterbalance to excitotoxic glutamate
Fibrinolysis	Decreases tissue plasminogen activator (tPA) antigen
VAT Selectivity	Preferentially targets visceral adipose tissue while preserving subcutaneous fat depots

A Note on 11β-HSD1 Inhibition

This often-overlooked mechanism is clinically significant. 11β-Hydroxysteroid dehydrogenase type 1 (11β-HSD1) is an intracellular enzyme that converts inactive cortisone to active cortisol — particularly active in muscle and brain tissue. Tesamorelin's inhibition of this pathway reduces intracellular cortisol activation associated with cellular stressors, potentially influencing metabolism and immune function independently of the peripheral adrenal axis.

Tesamorelin vs. Exogenous Growth Hormone

Parameter	Tesamorelin (GHRH)	Exogenous GH
GH Pattern	Pulsatile (physiological)	Continuous, supraphysiologic
Feedback Inhibition	Preserved (somatostatin intact)	Suppressed
IGF-1 Levels	Normal age-adjusted range	Often supraphysiologic (>3 SDS)
Glucose Homeostasis	Preserved — no insulin resistance	Impaired — insulin resistance common

VAT Effect	Selective reduction (spares SAT)	General lipolysis including SAT
Subcutaneous Fat	Preserved	Reduced (may be undesirable)
Malignancy Risk	Lower theoretical risk	Concern with elevated IGF-1
Dosing	Once daily SC	Daily SC injection

SECTION 3 · POINTS OF CLINICAL RELEVANCE

- **1.** Selective visceral fat reduction without subcutaneous fat loss.

Tesamorelin preferentially targets VAT — the metabolically active, pro-inflammatory fat depot linked to cardiovascular risk, insulin resistance, and fatty liver disease — while preserving subcutaneous fat. This avoids the 'Ozempic face' or gaunt appearance sometimes seen with exogenous GH or GLP-1 agents.

- **2.** Physiological GH axis maintenance is its defining clinical advantage.

By working through the hypothalamic-pituitary axis rather than bypassing it, tesamorelin preserves the pulsatile secretion of GH and the natural somatostatin/IGF-1 feedback loop. IGF-1 remains within age-adjusted normal limits, reducing the risk of the adverse effects associated with chronic GH excess.

- **3.** Glucose safety — even in type 2 diabetic patients.

In a 12-week RCT (Clemmons et al., PLoS One 2017, N=53 T2DM patients), tesamorelin produced no significant changes in insulin response, HbA1c, or diabetes control. Total cholesterol and non-HDL cholesterol decreased significantly. No patient discontinued due to loss of glycemic control.

- **4.** Hepatic fat reduction with anti-fibrotic potential.

The NAFLD-in-HIV trial (Stanley et al., Lancet HIV 2019, N=61) demonstrated a 37% relative reduction in hepatic fat fraction and prevention of fibrosis progression — compared to 38% fibrosis progression in the placebo group. This is the first GHRH analog to demonstrate simultaneous VAT and liver fat reduction via a mechanistically linked pathway.

- **5.** Neurocognitive applications are supported by clinical data.

A 20-week RCT (Baker et al., Arch Neurol 2012, N=152) showed improvements in executive function (P=0.005) and cognition in both healthy older adults and patients with mild cognitive impairment (MCI). A companion trial (Friedman et al., JAMA Neurol 2013, N=30) demonstrated increased GABA in all 3 brain regions, reduced myo-inositol (an early Alzheimer's biomarker measurable by MRI), and increased N-acetylaspartate-glutamate in the dorsolateral frontal cortex.

- **6.** VAT reduction is the key driver of metabolic benefit.

Responder analysis (Stanley et al., CID 2012) showed that patients achieving ≥8% VAT reduction had significantly greater improvements in triglycerides, adiponectin, and glucose homeostasis compared to non-responders. The 8% VAT reduction threshold at 26 weeks defines clinical response and predicts sustained metabolic benefit.

- **7.** Ongoing therapy is generally required to maintain benefit.

Upon discontinuation, VAT reaccumulation occurs. In HIV-associated lipodystrophy, this typically necessitates continuous therapy. In non-HIV patients, addressing upstream contributors to visceral adiposity (dietary, stress-related, immune-mediated) may alter the durability of response.

SECTION 4 · GENERAL DOSING INSTRUCTIONS AND DELIVERY OPTIONS

FDA-Approved Formulations

Original Egrifta	2 mg SC daily — basis for most clinical trial data; FDA-approved 2010
Egrifta SV (4th formulation)	1.4 mg SC daily — bioequivalent to 2 mg; current standard formulation
Egrifta WR	1.28 mg SC daily — bioequivalent to 2 mg; depot-style absorption from subcutaneous tissue for more sustained release
Cognitive Research Dose	1 mg SC daily before bed — used in Baker/Friedman neurocognitive trials

Administration Protocol

- Reconstitution: Use provided sterile water for injection. Gently swirl — do not shake. Allow 20 minutes for complete reconstitution. Solution should be clear.
- Injection site: Subcutaneous into the abdomen only (or the hip/flank area). Rotate sites with each injection to prevent lipohypertrophy and scar tissue.
- Frequency: Once daily. Timing can be consistent morning dosing or before bed to align with nocturnal GH secretion.
- Storage: Refrigerate lyophilized vials (2–8°C). Protect from light. Do not freeze. Once reconstituted: use immediately, or within 24 hours if refrigerated (note: multi-dose storage varies by formulation).

Cycling Recommendations (Off-Label Clinical Guidance)

While no definitive cycling protocol has been established in trials, clinical guidance suggests:

- Standard cycling: 5 out of 7 days per week
- Option A: 4 weeks on, 1 week off
- Option B: 12 weeks on, 4–6 weeks off (particularly recommended for the Egrifta WR depot formulation due to potential long-term effects on pulsatility)

Cycling strategies aim to preserve pituitary responsiveness and avoid tachyphylaxis, particularly relevant when using sustained-release depot preparations.

A Note on Egrifta WR

Unlike the standard formulations, Egrifta WR does not have a longer biological half-life — rather, it sits longer in the subcutaneous depot before being absorbed, creating a slower systemic release. Over extended use, this more sustained exposure may theoretically exert greater pressure on the natural feedback axis. Incorporating a structured cycle break is advisable.

SECTION 5 · EVIDENCE PROFILE

Clinical Trial Evidence

Category	Study / Evidence	Key Finding
Phase 3 RCT	Falutz et al., JCEM 2010 (N=816, 26-week + 26-week extension)	VAT: −17.5% at 26 weeks (P<0.001); 69% responder rate; sustained at 52 weeks; triglycerides and cholesterol improved; VAT reaccumulates on discontinuation

Visceral + Liver RCT	Stanley et al., JAMA 2014 (N=48, 6 months)	VAT: −16.6% net effect; first trial demonstrating simultaneous VAT and hepatic fat reduction; liver fat change correlated with VAT change (r=0.31)
NAFLD/HIV RCT	Stanley et al., Lancet HIV 2019 (N=61, 12 months)	Hepatic fat fraction: −37% relative reduction; fibrosis progression prevented; improved CRP; NIH-sponsored
GH Pulsatility	Stanley et al., JCEM 2011 (N=13, 2 weeks)	Augmented basal and pulsatile GH secretion; IGF-1 within normal range; insulin-stimulated glucose uptake preserved
Metabolic Responders	Stanley et al., CID 2012	Responders (≥8% VAT) showed significantly better triglycerides, adiponectin, and glucose vs. non-responders
T2DM Safety	Clemmons et al., PLoS One 2017 (N=53, 12 weeks)	No significant change in HbA1c, insulin response, or fasting glucose; total and non-HDL cholesterol decreased
Cognition	Baker et al., Arch Neurol 2012 (N=152, 20 weeks)	Improved executive function (P=0.005); benefits in both MCI and healthy older adults
Neuroprotection	Friedman et al., JAMA Neurol 2013 (N=30, 20 weeks)	Increased GABA in 3 brain regions (P<0.04); reduced myo-inositol in posterior cingulate (P=0.002); IGF-1 correlated with GABA changes
Muscle Quality	Adrian et al., J Frailty Aging 2019	Increased muscle density and area in all 4 trunk muscle groups; phosphocreatine recovery kinetics improved (mitochondrial function)
Review / BioDrugs	Dhillon, BioDrugs 2011	Comprehensive pharmacological review; regulatory synthesis

Evidence Classification Summary

- Phase 3 RCT data: Strong — for HIV-associated lipodystrophy VAT reduction (primary FDA indication)
- Phase 2–3 RCT data: Moderate-to-Strong — for hepatic fat and NAFLD endpoints
- RCT data: Moderate — for cognitive and neuroprotective outcomes (smaller N, single trials)
- RCT data: Moderate — for glucose safety in T2DM (12-week duration)
- Preclinical / mechanistic: Supporting — for 11β-HSD1 inhibition, AMPK/mitochondrial pathways
- In vitro: Limited but consistent — mechanistic pathway validation for GHRHR signaling

Critical Gaps in the Evidence

- Long-term safety beyond 52 weeks: No extended trials exist. Effects on IGF-1, glucose metabolism, and potential malignancy risk over multi-year use remain undefined.
- Non-HIV general population: Most data comes from HIV-associated lipodystrophy. Dedicated RCTs for metabolic syndrome, non-HIV obesity, and general NAFLD are lacking.
- NASH-specific histologic trials: Hepatic fat reduction is demonstrated, but formal NASH endpoint trials (required for regulatory approval in liver disease) have not been completed.
- Optimal cycling and discontinuation strategies: No RCT data on cycling protocols or the best strategies for maintaining benefit after stopping therapy.

- Long-term cognitive outcomes: The GABA modulation and executive function improvements are from short 20-week trials; durable neuroprotective effects are not yet established.
- Pediatric use: Not established; formal study with open epiphyses has not been validated.

SECTION 6 · CLINICAL CONSIDERATIONS

Absolute Contraindications

- Pregnancy: Contraindicated — may cause fetal harm; visceral fat increase is physiological during pregnancy
- Active Malignancy: Contraindicated — treatment must be completed before initiating tesamorelin
- Disrupted HPA Axis: Contraindicated — hypophysectomy, pituitary tumor or surgery, head irradiation, significant head trauma
- Hypersensitivity: Discontinue immediately if reaction to tesamorelin or mannitol (present as an excipient in the formulation)

Warnings and Precautions

- Fluid retention / peripheral edema: GH-mediated; may manifest as edema, carpal tunnel syndrome, or paresthesias — monitor closely, adjust dose if needed
- Acute critical illness: Increased mortality risk is a class effect of GH axis agents — do not initiate or continue in critically ill patients
- Children with open epiphyses: Not for use in pediatric patients with unfused growth plates
- Pre-existing diabetes: Monitor HbA1c and fasting glucose closely; transient glucose increases have been observed

Adverse Effect Profile (Frequency >5%)

Injection site reactions	Rotate sites; avoid scar tissue and the navel area
Arthralgia	Dose-related; usually transient; reduce dose if persistent
Myalgia	Usually transient; monitor and reassure
Peripheral edema	GH-mediated fluid retention; monitor for carpal tunnel symptoms
Paresthesia / CTS	Consider dose adjustment if significant
Headache	Usually resolves with continued use
Transient glucose increase	Monitor HbA1c; usually normalizes by 52 weeks
IGF-1 elevation	Discontinue if persistent elevation >3 standard deviations above normal

Patient Selection

Ideal candidates:

- HIV-infected patients with confirmed excess visceral adiposity (clinical or imaging)
- Patients on stable ART regimen (>8 weeks)
- Non-HIV patients with visceral adiposity (emerging indication)
- Patients with NAFLD/NASH and elevated hepatic fat fraction
- Patients with mild cognitive impairment or at-risk for cognitive decline (research context)
- Intact hypothalamic-pituitary axis confirmed

Exclude if:

- Active malignancy or untreated prior malignancy
- Pregnancy or planning pregnancy
- Disrupted hypothalamic-pituitary axis
- Hypersensitivity to tesamorelin or mannitol
- Open epiphyses (pediatric)
- Acute critical illness

Monitoring Framework

Baseline Labs	IGF-1, fasting glucose, HbA1c, lipid panel (triglycerides, total cholesterol, non-HDL), liver enzymes
Baseline Imaging	Waist circumference, CT scan for VAT quantification (if available), InBody or DXA for body composition, bone density
Weeks 4–8	IGF-1 (maintain <3 SDS above normal); assess tolerability: injection site, edema, arthralgia
Week 12	HbA1c, fasting glucose, lipid panel; document body composition changes
Week 26	Define responder status (≥8% VAT reduction); if non-responder, re-evaluate continuation or consider alternative approach
Ongoing (Long-term)	Periodic IGF-1, glucose/HbA1c, lipid panels; InBody quarterly for lean mass and VAT trends; watch for VAT reaccumulation
Special Monitoring	For cognitive indications: consider specialized MRI evaluation of myo-inositol, N-acetylaspartate, and NAA-glutamate levels in relevant brain regions

Charting and Documentation Framework

The SSRP Institute recommends tracking the following in clinical notes for every patient on tesamorelin:

- Route of administration and formulation (Egrifta SV vs. WR vs. compounded)
- Dosing cycle and duration (e.g., 5/7 days; 12 weeks on / 4–6 weeks off)
- Baseline and serial IGF-1, HbA1c, fasting glucose, lipids, liver enzymes
- Visceral adiposity measures: waist circumference, InBody, CT imaging
- Lean muscle mass changes
- Cognitive markers if applicable
- Any adverse effects and management decisions

SECTION 7 · A FINAL NOTE

> ***Tesamorelin represents a fundamentally different philosophy in growth hormone axis medicine: working with the body's own regulatory architecture rather than bypassing it.***

Its defining strength — preserving pulsatile GH secretion and intact feedback inhibition — is not merely a pharmacological footnote. It is the mechanism that explains why tesamorelin achieves selective visceral fat reduction without the glucose dysregulation, supraphysiologic IGF-1 elevation, and subcutaneous fat loss that accompany exogenous growth hormone use.

The clinical story of tesamorelin is still being written. Its FDA approval in HIV-associated lipodystrophy provided rigorous Phase 3 validation and established a mechanistic foundation. The emerging evidence in NAFLD, cognitive function, neuroprotection, and muscle quality suggests a compound whose therapeutic utility may extend well beyond its current indication — but it is essential to acknowledge that this extension-of-use rests on smaller, shorter-duration trials and requires dedicated study before it can be routinely recommended.

For practitioners working in metabolic, longevity, or functional medicine, tesamorelin offers a compelling tool — particularly for patients with visceral adiposity, fatty liver disease, or early cognitive concerns — provided it is used within the bounds of evidence, with appropriate patient selection, thorough baseline assessment, structured monitoring, and an honest accounting of what is known and what remains unknown.

> *The visceral fat connection to systemic metabolic disease — from insulin resistance to hepatic steatosis to neuroinflammation — gives tesamorelin a uniquely central target. Addressing upstream drivers of visceral adiposity alongside pharmacological intervention will determine whether the benefits of therapy outlast its use.*

References

1. Falutz J et al. Tesamorelin pooled phase 3 analysis. J Clin Endocrinol Metab 2010;95(9):4291–304.
2. Falutz J et al. Tesamorelin in HIV abdominal fat accumulation. J Acquir Immune Defic Syndr 2010;53(3):311–22.
3. Stanley TL et al. Tesamorelin on visceral and liver fat in HIV. JAMA 2014;312(4):380–9.
4. Stanley TL et al. Tesamorelin on NAFLD in HIV. Lancet HIV 2019;6(12):e821–e830.
5. Stanley TL et al. Tesamorelin on inflammatory markers in HIV. AIDS 2011;25(10):1281–8.
6. Stanley TL et al. Visceral adiposity reduction and metabolic profile. Clin Infect Dis 2012;54(11):1642–51.
7. Stanley TL et al. GHRH analog effects on GH pulsatility. J Clin Endocrinol Metab 2011;96(1):150–8.
8. Baker LD et al. GHRH effects on cognitive function in MCI. Arch Neurol 2012;69(11):1420–9.
9. Friedman SD et al. GHRH effects on brain GABA levels. JAMA Neurol 2013;70(7):883–90.
10. Clemmons DR et al. Tesamorelin safety in type 2 diabetes. PLoS One 2017;12(6):e0179538.
11. Dhillon S. Tesamorelin in HIV-associated lipodystrophy. BioDrugs 2011;25(6):405–8.
12. Adrian S et al. Tesamorelin on muscle fat and area in HIV. J Frailty Aging 2019;8(3):154–159.